Larvol Delta - Climb-Bio-Expands-Pipeline-Through-an-Exclusive-License-to-Develop-and-Commercialize-an-Antibody-Targeting-the-APRIL-Pathway-for-IgA-Nephropathy

CLYM116 - Climb Bio

https://www.globenewswire.com/news-release/2025/01/09/3006952/0/en/Climb-Bio-Expands-Pipeline-Through-an-Exclusive-License-to-Develop-and-Commercialize-an-Antibody-Targeting-the-APRIL-Pathway-for-IgA-Nephropathy.html

Jan 9, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next